Tilray expands medical cannabis portfolio in Australia

Executive Summary

• Tilray Medical announced its largest portfolio expansion in Australia to date, reinforcing its commitment to the local market and aiming to increase patient access to regulated medical cannabis.
• The expansion involves introducing new products under the Redecan and Good Supply brands across multiple formats, including flower, extracts, vapes, and pastilles.
• The move aligns with rising demand in Australia's regulated medical system and leverages Tilray's existing EU-GMP certified supply chains and local expertise.

Key Details

• Strategic Significance: Described as the "largest portfolio expansion in Australia to date" by Tilray Medical.
• Brand Portfolio: New products will be introduced under two primary brands:
  • Redecan: Will include medical cannabis flower, extracts, vapes, and pastilles.
  • Good Supply: Will introduce new medical cannabis flower offerings.
• Product Focus: The expansion targets high-potency, patient-focused solutions and aims to enhance treatment options for healthcare professionals and patients.
• Operational Context: Tilray Medical has operated in Australia for several years, supplying EU-GMP certified medical cannabis through established prescriber, pharmacy, and clinical distribution channels.
• Market Rationale: The expansion is aligned with rising demand across Australia's regulated medical system and supports the company's long-term international growth strategy.

Notable Quotes

• Rajnish Ohri, President, International, Tilray Brands: "Australia represents an important strategic market within our international growth strategy. This launch reflects our long-term commitment to delivering quality, differentiated cannabis products."
• Rajnish Ohri, President, International, Tilray Brands: "By bringing together proven genetics, rigorous quality standards and our strong local market expertise, we are excited to support the evolving needs of the Australian community. This milestone reflects our continued investment across priority global markets, as we broaden access to trusted cannabis products worldwide."